 Jagar Jasem
Concepts (99)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Paralysis | 2 | 2014 | 69 | 0.850 |
Why?
| | Breast Neoplasms | 3 | 2017 | 2140 | 0.660 |
Why?
| | Carcinoma, Intraductal, Noninfiltrating | 1 | 2015 | 54 | 0.480 |
Why?
| | Sentinel Surveillance | 1 | 2014 | 41 | 0.450 |
Why?
| | Poliomyelitis | 1 | 2014 | 36 | 0.450 |
Why?
| | Facial Muscles | 1 | 2013 | 3 | 0.440 |
Why?
| | Guillain-Barre Syndrome | 1 | 2013 | 22 | 0.430 |
Why?
| | Gene Expression Profiling | 2 | 2017 | 1688 | 0.410 |
Why?
| | Measles | 1 | 2011 | 44 | 0.360 |
Why?
| | Liver Neoplasms | 1 | 2015 | 640 | 0.340 |
Why?
| | Iraq | 3 | 2014 | 52 | 0.320 |
Why?
| | Disease Outbreaks | 1 | 2011 | 349 | 0.300 |
Why?
| | Adenocarcinoma | 1 | 2015 | 898 | 0.300 |
Why?
| | Chemotherapy, Adjuvant | 2 | 2017 | 379 | 0.240 |
Why?
| | Lymphoma, T-Cell, Peripheral | 1 | 2024 | 16 | 0.220 |
Why?
| | Vaccination | 1 | 2011 | 1347 | 0.210 |
Why?
| | Neoplasm Staging | 2 | 2017 | 1290 | 0.200 |
Why?
| | Survival Analysis | 2 | 2016 | 1269 | 0.190 |
Why?
| | Immunotherapy, Adoptive | 1 | 2024 | 295 | 0.180 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2017 | 958 | 0.170 |
Why?
| | Rodenticides | 1 | 2019 | 4 | 0.160 |
Why?
| | Leukemia, Promyelocytic, Acute | 1 | 2019 | 12 | 0.160 |
Why?
| | Biomarkers, Tumor | 2 | 2017 | 1173 | 0.160 |
Why?
| | Vitamin K | 1 | 2019 | 41 | 0.160 |
Why?
| | Retrospective Studies | 7 | 2024 | 14461 | 0.160 |
Why?
| | Genetic Predisposition to Disease | 2 | 2018 | 2276 | 0.150 |
Why?
| | Fibrinogen | 1 | 2019 | 163 | 0.150 |
Why?
| | HELLP Syndrome | 1 | 2018 | 6 | 0.150 |
Why?
| | Atypical Hemolytic Uremic Syndrome | 1 | 2018 | 19 | 0.150 |
Why?
| | Heparin | 1 | 2019 | 253 | 0.140 |
Why?
| | Blood Coagulation Disorders | 1 | 2019 | 167 | 0.140 |
Why?
| | Female | 12 | 2024 | 68556 | 0.140 |
Why?
| | Incidence | 2 | 2014 | 2636 | 0.140 |
Why?
| | Germ-Line Mutation | 1 | 2018 | 140 | 0.140 |
Why?
| | Fanconi Anemia Complementation Group N Protein | 1 | 2017 | 5 | 0.140 |
Why?
| | Breast Neoplasms, Male | 1 | 2017 | 29 | 0.130 |
Why?
| | Middle Aged | 8 | 2024 | 31091 | 0.130 |
Why?
| | Neoplasm Grading | 1 | 2017 | 283 | 0.130 |
Why?
| | Risk Factors | 5 | 2019 | 9746 | 0.130 |
Why?
| | Lymphatic Metastasis | 1 | 2017 | 320 | 0.130 |
Why?
| | Database Management Systems | 1 | 2016 | 48 | 0.130 |
Why?
| | Alphapapillomavirus | 1 | 2016 | 40 | 0.120 |
Why?
| | Oropharyngeal Neoplasms | 1 | 2016 | 48 | 0.120 |
Why?
| | Posterior Leukoencephalopathy Syndrome | 1 | 2015 | 11 | 0.120 |
Why?
| | Aged | 7 | 2024 | 22032 | 0.120 |
Why?
| | Hemorrhage | 1 | 2019 | 678 | 0.120 |
Why?
| | Clinical Decision-Making | 1 | 2017 | 301 | 0.110 |
Why?
| | Odds Ratio | 1 | 2017 | 1019 | 0.110 |
Why?
| | Geography | 1 | 2014 | 186 | 0.110 |
Why?
| | Respiratory Muscles | 1 | 2013 | 32 | 0.110 |
Why?
| | Poliovirus | 1 | 2014 | 82 | 0.110 |
Why?
| | Male | 10 | 2024 | 63517 | 0.110 |
Why?
| | Receptor, ErbB-2 | 1 | 2016 | 326 | 0.110 |
Why?
| | Humans | 14 | 2024 | 129271 | 0.110 |
Why?
| | Receptors, Estrogen | 1 | 2016 | 426 | 0.100 |
Why?
| | Adolescent | 5 | 2018 | 20315 | 0.100 |
Why?
| | Clinical Trials as Topic | 1 | 2017 | 1004 | 0.100 |
Why?
| | Comorbidity | 1 | 2017 | 1544 | 0.100 |
Why?
| | Measles Vaccine | 1 | 2011 | 19 | 0.100 |
Why?
| | Seizures | 1 | 2015 | 401 | 0.090 |
Why?
| | Cost-Benefit Analysis | 1 | 2014 | 569 | 0.090 |
Why?
| | Infant | 3 | 2015 | 8975 | 0.090 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2016 | 625 | 0.090 |
Why?
| | Logistic Models | 1 | 2016 | 1985 | 0.090 |
Why?
| | Child | 4 | 2015 | 20785 | 0.090 |
Why?
| | Child, Preschool | 3 | 2015 | 10459 | 0.090 |
Why?
| | Population Surveillance | 1 | 2013 | 438 | 0.090 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2015 | 572 | 0.080 |
Why?
| | Prognosis | 1 | 2017 | 3773 | 0.080 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2015 | 592 | 0.080 |
Why?
| | Disease Progression | 1 | 2015 | 2630 | 0.070 |
Why?
| | Stroke | 1 | 2015 | 1070 | 0.070 |
Why?
| | Adult | 6 | 2019 | 35497 | 0.070 |
Why?
| | Mutation | 1 | 2017 | 3710 | 0.060 |
Why?
| | Tomography, X-Ray Computed | 1 | 2015 | 2515 | 0.060 |
Why?
| | Aged, 80 and over | 1 | 2017 | 7055 | 0.060 |
Why?
| | Time Factors | 1 | 2015 | 6543 | 0.060 |
Why?
| | Treatment Outcome | 2 | 2015 | 10202 | 0.060 |
Why?
| | Positron Emission Tomography Computed Tomography | 1 | 2024 | 84 | 0.050 |
Why?
| | Antigens, CD19 | 1 | 2024 | 114 | 0.050 |
Why?
| | Neoplasm, Residual | 1 | 2024 | 120 | 0.050 |
Why?
| | Lymphoma, B-Cell | 1 | 2024 | 105 | 0.050 |
Why?
| | Infant, Newborn | 1 | 2014 | 5736 | 0.050 |
Why?
| | Drug Contamination | 1 | 2019 | 51 | 0.040 |
Why?
| | Pilot Projects | 1 | 2024 | 1584 | 0.040 |
Why?
| | Complement C3b Inactivator Proteins | 1 | 2018 | 9 | 0.040 |
Why?
| | Purpura, Thrombotic Thrombocytopenic | 1 | 2018 | 12 | 0.040 |
Why?
| | Complement Inactivator Proteins | 1 | 2018 | 41 | 0.040 |
Why?
| | Cannabinoids | 1 | 2019 | 153 | 0.030 |
Why?
| | Blood Proteins | 1 | 2018 | 244 | 0.030 |
Why?
| | Analysis of Variance | 1 | 2018 | 1288 | 0.030 |
Why?
| | Transplantation, Homologous | 1 | 2015 | 400 | 0.030 |
Why?
| | Proportional Hazards Models | 1 | 2015 | 1197 | 0.020 |
Why?
| | Algorithms | 1 | 2019 | 1613 | 0.020 |
Why?
| | Multivariate Analysis | 1 | 2015 | 1497 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2018 | 3377 | 0.020 |
Why?
| | Young Adult | 2 | 2018 | 12392 | 0.020 |
Why?
| | Prospective Studies | 1 | 2018 | 7123 | 0.020 |
Why?
| | Pregnancy | 1 | 2018 | 6391 | 0.020 |
Why?
|
|
Jasem's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|